Pharmacovigilance update;Pharmacovigilance

Revue Medicale Suisse

Volumn 10, Issue 412-413, 2014, Pages 119-122

  Diezi, L ^a   Renard, D ^a   Rothuizen, L E ^a   Livio, F ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; DABIGATRAN; FINGOLIMOD; LAROPIPRANT PLUS NICOTINIC ACID; NITROFURANTOIN; PIGMENT; RETIGABINE; RITUXIMAB; ROFLUMILAST; TELAPREVIR; TOLVAPTAN; ZOLPIDEM;

ARTICLE; CREATININE CLEARANCE; DEATH; DRUG MARKETING; DRUG SURVEILLANCE PROGRAM; HUMAN; LEUKOENCEPHALOPATHY; LIVER TOXICITY; MECHANICAL HEART VALVE; MONITORING; MOOD DISORDER; QT PROLONGATION; RETINA; RISK; SKIN MANIFESTATION; UNSPECIFIED SIDE EFFECT;

AMINOPYRIDINES; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AZITHROMYCIN; BENZAMIDES; CARBAMATES; CYCLOPROPANES; HUMANS; NITROFURANTOIN; OLIGOPEPTIDES; PHARMACOVIGILANCE; PHENYLENEDIAMINES; PYRIDINES;

EID: 84893226544     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Gupta K, Hooton TM, Naber KG, et al. Executive summary: International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society of Microbiology and Infectious Diseases. Clin Infect Dis 2011;52:561-4.
2. Geerts AFJ, Eppenga WL, Heerdink R, et al. Ineffectiveness and adverse events of nitrofurantoin in women with urinary tract infection and renal impairment in primary care. Eur J Clin Pharmacol 2013;69:1701-7.
3. &z.ast; Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013;369:1206-14.
4. www.swissmedic.ch/marktueberwachung/00091/00092/02378/index.html?lang=fr (consulté en novembre 2013).
5. Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;366:1881-90.
6. &z.ast; Farkas RH, Unger EF, Temple R. Zolpidem and driving impairment - Identifying persons at risk. N Engl J Med 2013;369:689-91.
7. Daxas (roflumilast) tablets. DA 22 22-522 Pulmonary. Pulmonary-Allergy Drugs Advisory Committee Meeting April 7, 2010. URL: www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary- AllergyDrugsAdvisoryCommittee/UCM208711.pdf (consulté en septembre 2013).
8. Medicines and Healthcare Products Regulatory Agency. Drug Safety Update. Roflumilast (Daxas): Risk of suicidal behavior - avoid use in patients with previous or existing psychiatric symptoms and discontinue treatment if new or worsening psychiatric symptoms occur. January 2013. URL: www.mhra.gov.uk/Safety- information/DrugSafetyUpdate/CON228753 (consulté en septembre 2013).
9. https://tools.who-umc.org/webroot/ (consulté en septembre 2013).
10. ** Faulkner MA, Burke RA. Safety profile of two novel antiepileptic agents approved for the treatment of refractory partial seizures: Ezogabine (retigabine) and perampanel. Expert Opin Drug Saf 2013;12:847-55.
11. www.swissmedic.ch/marktueberwachung/00091/00092/02439/index.html?lang=fr (consulté en novembre 2013).
12. www.swissmedic.ch/marktueberwachung/00091/00092/02362/index.html?lang=fr (consulté en novembre 2013).
13. www.swissmedic.ch/marktueberwachung/00091/00092/02370/index.html?lang=fr (consulté en novembre 2013).
14. FDA Drug Safety Communication: FDA investigating rare brain infection in patients taking Gilenya (fingolimod). Safety announcement 8/29/2013. URL: www.fda.gov/Drugs/DrugSafety/ucm366529.htm (consulté en novembre 2013).
15. Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012;367:2407-18.
16. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25'673 high-risk patients of ER niacin/laropipirant: Trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013;34:1279-91.